Development & Exclusive License Agreement
Oct 15 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK :
* ENTERED CO-DEVELOPMENT & EXCLUSIVE LICENSE AGREEMENT WITH
ESSEX
BIO-INVESTMENT & ZHUHAI ESSEX BIO-PHARMACEUTICAL
* TO CO-DEVELOP HLX04 AS THERAPY FOR EYE DISEASES WITH ESSEX
* CO ENTITLED TO GET SIGNING PAYMENT OF US$10 MILLION AND
REGULATORY MILESTONE PAYMENTS OF NOT MORE THAN US$15 MILLION
Source text for Eikon: ID:nHKS1pTWvn
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share